A federal judge in Manhattan halted the Justice Department from obtaining medical records of transgender patients treated at two major New York City hospital systems, ruling that criminal subpoenas issued by a Texas grand jury likely violated constitutional protections against unreasonable searches and compelled self-incrimination.
U.S. District Judge Katherine Polk Failla granted a temporary restraining order on Tuesday that bars federal prosecutors from seeking, receiving, using, retaining, or sharing identifying or sensitive patient information tied to gender dysphoria treatments. The order covers patients treated at NYU Langone Hospitals and Mount Sinai Health System facilities, and the judge certified the case as a class action, with at least 40 individuals at NYU Langone alone falling within the subpoenas' scope.
A hearing on whether to convert the temporary block into a longer preliminary injunction is set for July 8. Until then, the DOJ's criminal probe into how those hospitals administered gender-related treatments to minors is frozen in place.
The subpoenas originated from the U.S. Attorney's Office for the Northern District of Texas and were issued under a federal grand jury sitting in Fort Worth. The Associated Press reported that prosecutors sought records spanning more than six years, from January 1, 2020, through May 5, 2026, as part of a criminal investigation into potential "misbranding" of FDA-approved drugs used in gender dysphoria treatment for patients under 18.
The misbranding theory centers on whether hospitals prescribed drugs approved by the Food and Drug Administration for one purpose but administered them for gender-related treatments without proper labeling or authorization. Federal law treats certain off-label prescribing practices as potential criminal violations when drugs are introduced into commerce with false or misleading labeling.
The breadth of the records request drew immediate legal challenges. Plaintiffs, represented by attorneys including the ACLU, argued that the subpoenas were not a good-faith criminal inquiry but a backdoor attempt to collect sensitive personal data after the administration failed to obtain similar information through civil channels.
Judge Failla, who sits in the Southern District of New York, found that the plaintiffs were likely to succeed on claims rooted in the Fourth and Fifth Amendments. The Fourth Amendment argument hinged on the sweeping nature of the subpoenas and the deeply private character of the medical records sought. The Fifth Amendment claim involved the risk that patients or their families could be forced to produce information that might later be used against them in criminal proceedings.
The judge went further in her written findings. She stated that the current administration "sought to demonize and eradicate an entire population of transgender individuals" from its earliest days in office, as Breitbart reported. That language framed her conclusion that the DOJ had turned to criminal subpoenas only after civil attempts to access similar records were "repeatedly rejected by courts."
The distinction matters legally. Grand jury subpoenas carry enormous compulsory force, and courts rarely intervene to block them. For Judge Failla to do so at the temporary restraining order stage signals that she views the government's conduct as constitutionally deficient, not merely aggressive.
The ruling lands in a broader pattern that has frustrated the Trump administration across multiple policy fronts. Federal judges have repeatedly stepped in to halt executive actions, from a Clinton-appointed judge blocking Trump's $1.776 billion anti-weaponization fund to courts intervening on immigration enforcement and agency restructuring.
For conservatives who support the DOJ's investigation into pediatric gender medicine, the decision raises a familiar question: whether district judges are substituting their own policy preferences for legitimate law enforcement discretion. Grand jury investigations are supposed to operate with broad latitude. Prosecutors ordinarily do not need to justify their investigative theories to a judge before issuing subpoenas.
Judge Failla's order, however, rests on the premise that this investigation is different. Her finding that the government's motive was discriminatory, not merely investigative, transforms a routine procedural dispute into a constitutional showdown over executive power and medical privacy.
The DOJ has faced similar setbacks in other high-profile cases. A federal judge recently tossed smuggling charges against Abrego Garcia and called the prosecution "vindictive," prompting the department to pledge an appeal. Whether the DOJ will take the same posture here remains to be seen.
Plaintiffs' attorneys celebrated the ruling as a win for patient privacy. Omar Gonzalez-Pagan, a lawyer for the plaintiffs, called the decision:
"A victory for the basic privacy of our clients and all families like theirs across New York City."
Chase Strangio, co-director of the ACLU's LGBTQ and HIV Rights Project, framed the case as part of a longer campaign against transgender patients. Newsmax quoted Strangio saying:
"For the past year, the Trump administration has not only decided that it knows better than these families and their doctors what their medical needs are, but has also sought to obtain troves of sensitive information about patients in New York."
The Justice Department has not publicly commented on whether it will appeal the temporary restraining order or wait until the July 8 hearing to make its case for the subpoenas' validity.
At the core of the dispute is a tension that extends well beyond transgender medicine. The question of when federal prosecutors can pierce doctor-patient confidentiality through grand jury subpoenas touches every American who expects their medical records to stay private. Courts have long recognized that grand juries need broad investigative tools, but they have also held that constitutional limits still apply when the government's demands are sweeping or pretextual.
Judge Failla's order treats the DOJ's subpoenas as falling on the wrong side of that line. She found the government was not conducting a targeted criminal investigation but casting a wide net to gather personal data on an entire class of patients. The class-action certification reinforces that view, covering not just the named plaintiffs but all patients treated at NYU Langone and Mount Sinai who fall within the subpoenas' date range.
The case also highlights the growing judicial skepticism toward federal agencies that pursue policy goals through enforcement mechanisms after losing in civil litigation. If courts blocked the government from obtaining these records through regulatory channels, using a criminal grand jury to get the same information raises serious questions about prosecutorial good faith. That is the argument Judge Failla accepted, at least at this preliminary stage.
Conservative legal observers have noted the tension in another direction as well. Federal judges have shown willingness to block government actions across the ideological spectrum, from an Obama-appointed judge blocking SNAP junk food restrictions to rulings halting enforcement of campus speech codes. The common thread is district judges exercising expansive power to freeze executive action, often based on preliminary findings that may not survive full litigation.
The July 8 hearing will determine whether the temporary restraining order becomes a preliminary injunction, which would keep the subpoenas blocked for the duration of the lawsuit. The DOJ will need to convince Judge Failla that its investigation has a legitimate, non-discriminatory basis and that the records it seeks are sufficiently targeted to survive Fourth Amendment scrutiny.
If the judge grants a preliminary injunction, the government's options narrow to an appeal before the Second Circuit Court of Appeals. That process could take months and would test whether appellate judges share Judge Failla's view that the subpoenas crossed constitutional lines.
The case also raises the question of whether the DOJ's "misbranding" theory has legs as a criminal matter. Off-label prescribing is common across American medicine, and prosecutors would need to show that the hospitals' practices went beyond standard medical judgment into conduct that federal drug-labeling laws actually prohibit. Investigators have not publicly detailed the evidence supporting that theory, and courts have shown increasing willingness to scrutinize government enforcement actions that appear to target disfavored groups rather than genuine criminal conduct.
For now, the records stay locked. The patients stay anonymous. And the DOJ's criminal probe into pediatric gender medicine sits on ice, waiting for a judge to decide whether the government's subpoena power has limits that even a grand jury cannot cross.
When prosecutors lose in civil court and reach for the criminal toolkit to get the same result, the judiciary has every reason to ask hard questions about what the investigation is really after.
